skip to main content

Methotrexate safety tests — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMusculoskeletal TherapeuticsMethotrexate safety testsGPhC CRA

A patient starts methotrexate under shared care for rheumatoid arthritis. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Full blood count, liver function and renal function

This scenario assesses Methotrexate safety tests in a UK pharmacy practice context. Methotrexate can cause bone marrow suppression, hepatotoxicity and renal-related toxicity. The best answer is Full blood count, liver function and renal function because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.

Reference: BNF; NICE CKS